Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 6/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | CDC25B | P30305 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.45 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.45 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6656676 | 0.86 | MEN1 (0.68) | ALDH1A1HSD17B10TSHRMAPTMEN1 | |
| SCHEMBL18285205 | 0.86 | TSHR (0.56) | ALDH1A1HSD17B10TSHRMAPTMEN1 | |
| SCHEMBL3785486 | 0.84 | TSHR (0.53) | ALDH1A1HSD17B10TSHRMAPTMEN1 | |
| SCHEMBL17707775 | 0.84 | TSHR (0.53) | ALDH1A1HSD17B10TSHRMAPTMEN1 | |
| SCHEMBL17707777 | 0.84 | TSHR (0.53) | ALDH1A1HSD17B10TSHRMAPTMEN1 | |
| SCHEMBL17707781 | 0.84 | TSHR (0.53) | ALDH1A1HSD17B10TSHRMAPTMEN1 | |
| SCHEMBL27746873 | 0.83 | ALDH1A1 (0.61) | ALDH1A1HSD17B10TSHRMAPTMEN1 | |
| SCHEMBL23294948 | 0.82 | TSHR (0.51) | ALDH1A1HSD17B10TSHRMAPTMEN1 | |
| SCHEMBL29588719 | 0.82 | TSHR (0.51) | ALDH1A1HSD17B10TSHRMAPTMEN1 | |
| SCHEMBL30954344 | 0.81 | MAPT (0.50) | ALDH1A1HSD17B10TSHRMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10227350-B2 | Phosphatidylinositol 3-kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-20180086768-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD SCIENCES, INC. | 2018-03-29 | — | — | US | disclosed |
| US-20180086768-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD SCIENCES, INC. | 2018-03-29 | — | — | US | disclosed |
| WO-2018057810-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2018-03-29 | — | — | WO | disclosed |
| US-20100298302-A1 | NOVEL PROTEIN KINASE MODULATORS | SENHWA BIOSCIENCES, INC. (TW) | 2010-11-25 | — | — | US | disclosed |
| WO-2010135571-A1 | NOVEL PROTEIN KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2010-11-25 | — | — | WO | disclosed |
| WO-2010135571-A1 | NOVEL PROTEIN KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2010-11-25 | — | — | WO | disclosed |
| US-20100298302-A1 | NOVEL PROTEIN KINASE MODULATORS | SENHWA BIOSCIENCES, INC. (TW) | 2010-11-25 | — | — | US | disclosed |
| US-20100298302-A1 | NOVEL PROTEIN KINASE MODULATORS | SENHWA BIOSCIENCES, INC. (TW) | 2010-11-25 | — | — | US | disclosed |
| EP-0882718-B1 | BENZIMIDAZOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO (JP) | 2005-08-31 | — | — | EP | disclosed |
| US-6352985-B1 | CARDIOVASCULAR DISORDERS OR GASTROINTESTINAL DISORDERS, DIABETES (TYPE II DIABETES), DIABETIC COMPLICATIONS METHOD FOR LOWERING THE BLOOD SUGAR LEVEL OF A PATIENT, | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-03-05 | — | — | US | disclosed |
| US-6166219-A | Benzimidazole derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-12-26 | — | — | US | disclosed |
| EP-0882718-A1 | BENZIMIDAZOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10227350-B2 | Phosphatidylinositol 3-kinase inhibitors | PIK3CA, AKT3, AKT1 | ALDH1A1 4716/4885HSD17B10 3775/4885TSHR 767/4885 |
| US-20180086768-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | PIK3CA, AKT3, AKT1 | ALDH1A1 4716/4885HSD17B10 3775/4885TSHR 767/4885 |
| US-20100298302-A1 | NOVEL PROTEIN KINASE MODULATORS | PIM2, PIM1, PIM3 | ALDH1A1 4648/4885HSD17B10 4414/4885TSHR 3763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.